Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure — United States (Including U.S. Territories), July 2017

CDC has updated the interim guidance for U.S. health care providers caring for pregnant women with possible Zika virus exposure in response to 1) declining prevalence of Zika virus disease in the World Health Organization's Region of the Americas (Americas) and 2) emerging evidence indicating prolonged detection of Zika virus immunoglobulin M (IgM) antibodies. Zika virus cases were first reported in the Americas during 2015-2016; however, the incidence of Zika virus disease has since declined. As the prevalence of Zika virus disease declines, the likelihood of false-positive test results increases. In addition, emerging epidemiologic and laboratory data indicate that, as is the case with other flaviviruses, Zika virus IgM antibodies can persist beyond 12 weeks after infection. Therefore, IgM test results cannot always reliably distinguish between an infection that occurred during the current pregnancy and one that occurred before the current pregnancy, particularly for women with possible Zika virus exposure before the current pregnancy. These limitations should be considered when counseling pregnant women about the risks and benefits of testing for Zika virus infection during pregnancy. This updated guidance emphasizes a shared decision-making model for testing and screening pregnant women, one in which patients and providers work together to make decisions about testing and care plans based on patient preferences and values, clinical judgment, and a balanced assessment of risks and expected outcomes.

[1]  C. Moore,et al.  Serial Head and Brain Imaging of 17 Fetuses With Confirmed Zika Virus Infection in Colombia, South America. , 2017, Obstetrics and gynecology.

[2]  Marie Bottomley Hartel,et al.  Evaluation of Placental and Fetal Tissue Specimens for Zika Virus Infection — 50 States and District of Columbia, January–December, 2016 , 2017, MMWR. Morbidity and mortality weekly report.

[3]  M. Biggerstaff,et al.  Pregnancy Outcomes After Maternal Zika Virus Infection During Pregnancy — U.S. Territories, January 1, 2016–April 25, 2017 , 2017, MMWR. Morbidity and mortality weekly report.

[4]  R. Césaire,et al.  Analysis of blood from Zika virus-infected fetuses: a prospective case series. , 2017, The Lancet. Infectious diseases.

[5]  Marie Bottomley Hartel,et al.  Vital Signs: Update on Zika Virus–Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure — U.S. Zika Pregnancy Registry, 2016 , 2017, MMWR. Morbidity and mortality weekly report.

[6]  Jisoo Kim,et al.  Zika Virus Transmission — Region of the Americas, May 15, 2015–December 15, 2016 , 2017, MMWR. Morbidity and mortality weekly report.

[7]  R. Link-Gelles,et al.  Establishing a Timeline to Discontinue Routine Testing of Asymptomatic Pregnant Women for Zika Virus Infection — American Samoa, 2016–2017 , 2017, MMWR. Morbidity and mortality weekly report.

[8]  R. DeBiasi,et al.  Zika Virus Infection With Prolonged Maternal Viremia and Fetal Brain Abnormalities , 2017 .

[9]  H. Kamel,et al.  First cases of Zika virus–infected US blood donors outside states with areas of active transmission , 2017, Transfusion.

[10]  R. Lanciotti,et al.  Zika Virus RNA Replication and Persistence in Brain and Placental Tissue , 2017, Emerging infectious diseases.

[11]  J. Muñoz-Jordán,et al.  Persistence of Zika Virus in Body Fluids — Preliminary Report , 2017 .

[12]  T. Pumarola,et al.  Prolonged Zika Virus Viremia during Pregnancy. , 2016, The New England journal of medicine.

[13]  Jennifer L. White,et al.  Zika Virus Testing Considerations: Lessons Learned from the First 80 Real-Time Reverse Transcription-PCR-Positive Cases Diagnosed in New York State , 2016, Journal of Clinical Microbiology.

[14]  John T Brooks,et al.  Update: Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika Virus for Persons with Possible Zika Virus Exposure - United States, September 2016. , 2016, MMWR. Morbidity and mortality weekly report.

[15]  J. Rakeman,et al.  Prolonged Detection of Zika Virus RNA in Pregnant Women , 2016, Obstetrics and gynecology.

[16]  S. Rasmussen,et al.  Update: Interim Guidance for the Evaluation and Management of Infants with Possible Congenital Zika Virus Infection - United States, August 2016. , 2016, MMWR. Morbidity and mortality weekly report.

[17]  C. Beard,et al.  Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure - United States, July 2016. , 2016, MMWR. Morbidity and mortality weekly report.

[18]  T. Pumarola,et al.  Zika virus infection in pregnant women in Barcelona, Spain. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  A. Powers,et al.  Zika Virus Disease in Colombia - Preliminary Report. , 2016, The New England journal of medicine.

[20]  S. Hills,et al.  Interim Guidance for Interpretation of Zika Virus Antibody Test Results. , 2016, MMWR. Morbidity and mortality weekly report.

[21]  C. Blackmore,et al.  Comparison of Test Results for Zika Virus RNA in Urine, Serum, and Saliva Specimens from Persons with Travel-Associated Zika Virus Disease - Florida, 2016. , 2016, MMWR. Morbidity and mortality weekly report.

[22]  D. Musso,et al.  Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[23]  P. Gething,et al.  Risk factors for UK Plasmodium falciparum cases , 2014, Malaria Journal.

[24]  C. Woods False-Positive Results for Immunoglobulin M Serologic Results: Explanations and Examples. , 2013, Journal of the Pediatric Infectious Diseases Society.

[25]  E. Massad,et al.  Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries , 2011, Malaria Journal.

[26]  R. Lanciotti,et al.  Genetic and Serologic Properties of Zika Virus Associated with an Epidemic, Yap State, Micronesia, 2007 , 2008, Emerging infectious diseases.

[27]  A. Noga,et al.  West Nile virus infection and serologic response among persons previously vaccinated against yellow fever and Japanese encephalitis viruses. , 2005, Vector borne and zoonotic diseases.

[28]  Denise A. Martin,et al.  Persistence of Virus-Reactive Serum Immunoglobulin M Antibody in Confirmed West Nile Virus Encephalitis Cases , 2003, Emerging infectious diseases.

[29]  N. Karabatsos,et al.  Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. , 1989, The Journal of general virology.

[30]  Y. Okuno,et al.  Serological studies on volunteers inoculated experimentally with a dengue virus strain in 1943. , 1983, Biken journal.

[31]  S. Halstead,et al.  Original antigenic sin in dengue. , 1983, The American journal of tropical medicine and hygiene.

[32]  T. Monath,et al.  Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. , 1981, Bulletin of the World Health Organization.